DDIT3 and diffuse large B-cell lymphoma: To further confirm the role of tucidinostat plus R-CHOP in DEL phenotype of DLBCL patients, a phase III, randomized, double-blind, placebo-controlled, multicenter study is currently ongoing in China (NCT04231448).